Incyte Corporation continues to beat expectations with strong revenue growth and margin expansion. Read why INCY stock is a ...

To soften the blow, CSPC has accelerated its shift from generic drugs to innovative medicines. In the first three quarters, ...

Novo and Lilly just slashed prices on GLP-1 weight-loss drugs that recently cost over $1,000 a month. What happened?

Activists urge India to waive clinical trial requirements for lenacapavir, as patent barriers threaten access to the vital ...

Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include ...

Pharmacy benefit managers (PBMs) are back in the crosshairs. PBMs negotiate drug prices down on behalf of consumers and insurers – to the ire of ...

The discounts should be compared against the drugs’ “ultimate net price” rather than their indicated list price to gauge the ...

The Ministry of Health, Labour and Welfare ("the MHLW") currently lacks sufficient legal experience to assess whether a generic product will, ...

Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience ...

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

73% lower for Trelegy Ellipta, which treats asthma and chronic obstructive pulmonary disease (COPD) and was taken by 1.3 million Medicare Part D enrollees last year. 60% lower for Pomalyst, which ...

On Tuesday, November 25, the Centers for Medicare & Medicaid Services (CMS) announced that it will reduce the cost of 15 prescription drugs for Medicare users in 2027. This cut is expected to save ...